Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

FDA

Positive Phase III Alzheimer's results send Lundbeck and Otsuka

Lundbeck, Otsuka drug cut agitation in Alzheimer's patients

Allison Rosenthal on LinkedIn: So proud and humbled to announce a

Gate Neurosciences opens lab in NorthShore Evanston Hospital

Craig Chepke, MD, DFAPA on LinkedIn: Otsuka and Lundbeck Announce

Otsuka and Lundbeck gain FDA approval for supplemental New Drug

Julie Moore on LinkedIn: We work for the patients but also the

Mischa Agster on LinkedIn: Otsuka Announces New FDA Approval

FDA Approves First Drug to Treat Agitation Symptoms Associated